Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
Mirum Pharmaceuticals, Inc. (MIRM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is how Albireo Pharma (ALBO) and Lantheus Holdings (LNTH) have performed compared to their sector so far this year.
Bylvay (odevixibat) granted Priority Review by U.S. FDAASSERT study demonstrated efficacy of Bylvay in pruritus, bile acids and sleep with a low drug-related diarrhea rate in Alagille patientsApproval in second indication would more than double Bylvay market opportunity BOSTON, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare disease company developing novel bile acid modulators to treat pediatric and adult liver diseases, today announced that the U.S. Food and Drug
Two somewhat under-the-radar biotech companies saw their share prices soar this week after agreeing to be acquired. CinCor Pharma (NASDAQ: CINC) is being bought out by deep-pocketed pharmaceutical company AstraZeneca, while Albireo Pharma (NASDAQ: ALBO) is set to be owned by France-based peer Ipsen. Both of these deals are very lucrative, to the point where CinCor's stock rocketed 146% over the course of the week, and Albireo shot 92% skyward, according to data compiled by S&P Global Market In...
(Bloomberg) -- Multiple small biopharmaceutical companies jumped by a record Monday after larger drugmakers scooped them up, marking a small flurry of activity in the M&A-hungry space as a key sector conference kicks off. Most Read from BloombergUS Safety Agency to Consider Ban on Gas Stoves Amid Health FearsGoldman to Cut About 3,200 Jobs This Week After Cost ReviewCommodity Ship Heads for Inspection After Suez Canal MishapStocks Give Up Rally Above Key Mark After Fedspeak: Markets WrapMorgan S
The annual JPMorgan Healthcare Conference in San Francisco, which kicked off today, is often a magnet for deal announcements. This year was no exception, though they were all of the smaller variety — mostly European drug companies paying big premiums to fill their pipelines. Among them, AstraZeneca PLC’s announcement that it would purchase CinCor Pharma Inc. for [as much as $1.8 billion](https://www.wsj.com/livecoverage/stock-market-news-today-01-09-2023/card/astrazeneca-to-buy-u-s-drugmaker-cin
Ipsen is set to acquire Albireo Pharma Inc., the rare liver disease-focused biopharma spun out of AstraZeneca in 2008, for about $952 million.
The Nasdaq Composite (NASDAQINDEX: ^IXIC) might finally be looking to gain some momentum in 2023, with investors desperately wanting a reversal from 2022's horrible performance. Sizable gains on Friday helped to build more positive sentiment, and the bullish move continued on Monday morning, with the Nasdaq rising 1.5% at midmorning. Big-name companies get the headlines most of the time, but sometimes, news of mergers and acquisitions pushes a little-known company into the spotlight.
Ipsen (OTC: IPSEY) has agreed to acquire Albireo Pharma Inc (NASDAQ: ALBO) at $42.00 per share in cash for an initial estimated aggregate consideration of $952 million plus one contingent value right (CVR) per share. Each CVR will entitle its holder to deferred cash payments of $10.00 per CVR payable upon the FDA approval of Bylvay in the Biliary Atresia indication at the latest by Dec. 31, 2027. The acquisition of Albireo will provide immediate incremental sales and strengthen Ipsen's rare dise
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...